1. Home
  2. SCLX vs ANIX Comparison

SCLX vs ANIX Comparison

Compare SCLX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$11.37

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.18

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
ANIX
Founded
2011
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.0M
104.0M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
SCLX
ANIX
Price
$11.37
$3.18
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$9.00
AVG Volume (30 Days)
75.9K
235.2K
Earning Date
11-14-2025
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,360,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$749.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$2.28
52 Week High
$34.27
$5.46

Technical Indicators

Market Signals
Indicator
SCLX
ANIX
Relative Strength Index (RSI) 31.18 40.61
Support Level $11.10 $3.07
Resistance Level $13.83 $3.36
Average True Range (ATR) 0.99 0.17
MACD -0.02 0.04
Stochastic Oscillator 8.28 23.08

Price Performance

Historical Comparison
SCLX
ANIX

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: